From January 1, 2024 to March 31, 2024, the company has repurchased 7,553,900 shares, representing 0.64% for CNY 67.18 million. With this, the company has completed the repurchase of 7,829,900 shares, representing 0.66% for CNY 69.72 million under the buyback announced on December 23, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.26 CNY | -0.96% | -2.48% | -11.75% |
May. 20 | Hisun Pharma's Veterinary Arm Gets Approval to Register Amoxicillin and Clavulanate Potassium Dry Suspension | MT |
May. 16 | Hisun Pharma's Veterinary Arm Gets Nod to Market Selamectin Drops | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.75% | 1.34B | |
+34.35% | 705B | |
+30.80% | 583B | |
-3.49% | 364B | |
+20.15% | 332B | |
+6.19% | 291B | |
+15.78% | 238B | |
-3.48% | 210B | |
+10.50% | 209B | |
+9.21% | 169B |
- Stock Market
- Equities
- 600267 Stock
- News Zhejiang Hisun Pharmaceutical Co., Ltd.
- Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023.